Evidence map›Paper›PMID 40102292›Full record

ArticleJournal of molecular neuroscience : MN2025

Wild-Type TP53 Predicts Poor Prognosis in Lower-Grade Glioma via TP53-CXCL14-GATA3 Axis.

Amr Ahmed El-Arabey, Samia S Alkhalil, Nouf Omar AlAfaleq, Sawsan Al-Shouli, Samah Saif Eldin M Mohamed, Samia T Al-Shouli, Mohnad Abdalla

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amr Ahmed El-ArabeyApplied College, King Khalid University, P. O. Box 9004, 61413, Abha, Saudi Arabia. ph.amrcapa@gmail.com.ORCID http://orcid.org/0000-0003-0420-7191
Samia S AlkhalilDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Alquwayiyah, Riyadh, Saudi Arabia.
Nouf Omar AlAfaleqBiochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia.
Sawsan Al-ShouliPharmacy Department, Security Forces Hospital, 11481, Riyadh, Saudi Arabia.
Samah Saif Eldin M MohamedClinical laboratory sciences department, College of Applied Medical Sciences/Alqwyiyah, Shaqra University, Riyadh, Saudi Arabia.
Samia T Al-ShouliImmunology Unit, Department of Pathology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. salshouli@ksu.edu.sa.ORCID http://orcid.org/0000-0002-3473-0883
Mohnad AbdallaResearch Institute of Pediatrics, Children's Hospital Affiliated to Shandong University (Jinan Children's Hospital), Jinan, 250022, China.

Funding

The authors extend their appreciation to the Deanship of Scientific Research at King Khalid University for funding this work through Large Groups (RGP.2/545/45). RGP.2/545/45
6 · The paper itself

Abstract

Low-grade gliomas (LGG) are malignant brain tumors that arise from the brain's support cells (glial cells). LGG are the most common kind of central nervous system tumors in children and adolescents, accounting for around half of all cases. Tumor Protein p53 (TP53) regulates or promotes DNA damage and repair via a variety of cell cycle, apoptosis, and genomic stability pathways. However, the clinical role of TP53 status in LGG patients is still unknown. Hence, we analyzed clinical data from the Cancer Genomic Atlas (TCGA) of LGG patients to see if TP53 status affects clinical outcomes, molecular signatures of chemokines and microRNAs, and immune cell infiltrations within the tumor's microenvironment of LGG patients. According to our findings, the most common phenotype in LGG patients is wild-type TP53, which is related to poor clinical outcomes and the expression of Chemokine ligand 14 (CXCL14) in many clinical parameters such as age, gender, stage, race, and purity. Besides, in LGG patients, wild-type TP53 controls prognostic microRNAs such as has-miR-10a-3p and has-miR-155-5p. Furthermore, through activating GATA Binding Protein 3 (GATA3) and decreasing Fatty Acid Synthase (FASN), wild-type TP53 orchestrates M1 macrophage and CD8

Indexed as

Brain NeoplasmsChemokines, CXCGATA3 Transcription FactorGliomaTumor Suppressor Protein p53FemaleHumansMaleMicroRNAsMiddle AgedPrognosisChemokines, CXCCXCL14 protein, humanGATA3 protein, humanGATA3 Transcription FactorMicroRNAsTP53 protein, humanTumor Suppressor Protein p53CXCL14GATA3Has-miR-10a-3pHas-miR-155-5pLGGTP53

Identifiers

PMID40102292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.